<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02359513</url>
  </required_header>
  <id_info>
    <org_study_id>1408170</org_study_id>
    <secondary_id>2015-000365-31</secondary_id>
    <nct_id>NCT02359513</nct_id>
  </id_info>
  <brief_title>Evaluation of the Efficacy of Serotoninergic Antidepressants in Bulimia Nervosa, According to Brain Serotonin Profile Determined by Positron Emission Tomography With [18F] MPPF.</brief_title>
  <official_title>Evaluation of the Efficacy of Serotoninergic Antidepressants in Bulimia Nervosa, According to Brain Serotonin Profile Determined by Positron Emission Tomography With [18F] MPPF - a Multicenter Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bulimia nervosa (BN) is a serious mental illness characterized by massive food crises
      followed by anxiety and compensatory behaviours (vomiting more often). Recent data show an
      increasing prevalence and a serious prognosis, due to excess mortality by suicide but also
      somatic complications.

      Two types of treatments are validated : serotoninergic antidepressants (SSRI) and
      psychotherapy. Many clinical trials confirm the effectiveness of the SSRI. But many studies
      also emphasize the important proportion of non-responders to SSRI, few of them analyze the
      reasons for this non-answer.

      To better understand the mode of action of SSRI, we should analyse the serotonergic activity
      in the central nervous system in bulimia. Recently, specific brain 5HT1A serotonin receptor
      ligands ([18F] MPPF or [11 C] WAY-100635), were used in positron emission tomography (PET) to
      characterize the serotonergic abnormalities of bulimic patients. The ligand [18F] MPPF has
      the feature to be sensitive to the level of endogenous serotonin.

      A first pilot study using PET with [18F] MPPF realized between the University Hospital of
      Saint Etienne and Lyon CERMEP showed a diffuse increase of the binding potential of [18F]
      MPPF in bulimic patients, suggesting a decrease in serotonin activity.

      The brain regions affected were angular gyrus, medial frontal cortex, left insula, cingulate
      gyrus and orbitofrontal gyrus. These areas are involved in major bulimic symptoms (impulse,
      taste, instinct, anxiety and satiety). However, we noticed an interindividual heterogeneity
      of cortical binding of [18F] MPPF.

      In front of the heterogeneity in terms of efficacity of SSRI and brain serotoninergic
      activity, it seems necessary to continues investigations, to determine if there is a link
      between brain serotonin profile and responding to SSRI in bulimia nervosa.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 9, 2015</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation between [18F]MPPF Binding Potential (BP) and efficacy of antidepressant treatment</measure>
    <time_frame>3 months</time_frame>
    <description>Correlation between efficacy of antidepressant treatment quantified by change from the baseline in number of bulimic crises and the change from the baseline in [18F]MPPF BP at 3 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation between [18F]MPPF Binding Potential (BP) and psychometric scores</measure>
    <time_frame>3 months</time_frame>
    <description>Correlation between change from the baseline in [18F]MPPF BP and change from the baseline in psychometric scores at 3 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between [18F]MPPF Binding Potential (BP) and initial severity</measure>
    <time_frame>3 months</time_frame>
    <description>Correlation between [18F]MPPF Binding Potential (BP) at 3 months and initial (month 0) disease severity quantified by numbers bulimic crises over last 2 weeks before the initial evaluation and psychometric scores at initial evaluation (day 0)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in [18F]MPPF Binding Potential (BP)</measure>
    <time_frame>3 months</time_frame>
    <description>Comparison between [18F]MPPF Binding Potential (BP) before antidepressant treatment (day 0) and after antidepressant treatment (month 3)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Bulimia Nervosa</condition>
  <arm_group>
    <arm_group_label>boulimic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Analyse of serotoninergic brain activity (determined by positron emission tomography using [18F]MPPF) from bulimic patients treated with serotoninergic antidepressants during 3 months. The serotoninergic brain activity is measured before adnd after the serotoninergic antidepressant treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antidepressants</intervention_name>
    <description>bulimic patients are treated during 3 months</description>
    <arm_group_label>boulimic</arm_group_label>
    <other_name>Fluoxetine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Positron Emission Tomography (PET)</intervention_name>
    <description>PET scan using [18F]MPPF is performed before and after (3 months)antidepressant treatment</description>
    <arm_group_label>boulimic</arm_group_label>
    <other_name>PET scan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient affiliated or entitled to a social security scheme

          -  Bulimic patients according to DSM-IV TR: minimum 2 bulimic crises (compulsive eating
             followed by compensatory behavior) / week for 3 weeks

          -  Patients who signed informed consent to the study

          -  BMI greater than or equal to 18.5 kg / m²

        Exclusion Criteria:

          -  Against-indication to the SSRI or fluoxetine

          -  SSRI consumption in the previous three months

          -  Other addiction (except tobacco, for reasons of feasibility)

          -  Diagnosis of binge eating disorder or EDNOS (DSM-IV-TR)

          -  Patients with heart failure

          -  Against-indication for PET and / or MRI: pacemaker, intracerebral clips, prosthesis
             made of ferromagnetic material or claustrophobia

          -  Subjects with suspected pregnancy or in the second half of their menstrual cycle in
             the absence of oral contraceptives; positive Β-HCG test before the exam
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bogdan GALUSCA, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU SAINT-ETIENNNE</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bogdan GALUSCA, MD</last_name>
    <phone>(0)477127594</phone>
    <phone_ext>33</phone_ext>
    <email>bogdan.galusca@chu-st-etienne.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Florence RANCON</last_name>
    <phone>(0)477120284</phone>
    <phone_ext>33</phone_ext>
    <email>florence.rancon@aliceadsl.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Groupement Hospitalier Est - HCL</name>
      <address>
        <city>Bron</city>
        <zip>69678</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohamed SAOUD, PhD</last_name>
      <phone>(0)472118064</phone>
      <phone_ext>+33</phone_ext>
      <email>mohamed.saoud@ch-le-vinatier.fr</email>
    </contact>
    <investigator>
      <last_name>Mohamed SAOUD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sylvain ICETA, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bérénice SEGRESTIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire BUIS, MD</last_name>
    </contact>
    <investigator>
      <last_name>Claire BUIS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thierry BOUGEROL, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Saint-Etienne</name>
      <address>
        <city>Saint-Etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bogdan GALUSCA, MD</last_name>
      <phone>0477127594</phone>
      <phone_ext>+33</phone_ext>
      <email>bogdan.galusca@chu-st-etienne.fr</email>
    </contact>
    <contact_backup>
      <last_name>Torrance SIGAUD, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Bogdan GALUSCA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Torrance SIGAUD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Catherine MASSOUBRE, PU-PH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bruno ESTOUR, PU-PH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Natacha GERMAIN, PU-PH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2015</study_first_submitted>
  <study_first_submitted_qc>February 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2015</study_first_posted>
  <last_update_submitted>October 17, 2017</last_update_submitted>
  <last_update_submitted_qc>October 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bulimia</keyword>
  <keyword>serotoninergic brain activity</keyword>
  <keyword>fluoxetine</keyword>
  <keyword>serotoninergic antidepressant</keyword>
  <keyword>brain serotonin profile</keyword>
  <keyword>positon emission tomography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bulimia</mesh_term>
    <mesh_term>Bulimia Nervosa</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antidepressive Agents</mesh_term>
    <mesh_term>Fluoxetine</mesh_term>
    <mesh_term>Serotonin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

